Rheumatoid arthritis (RA) is a complex, chronic autoimmune condition that causes pain, stiffness, and swelling that, in moderate to severe cases, limits motion and functionality. The TreatmentTrends®: Rheumatoid Arthritis 2015 (EU5) report provides valuable insight into the treatment dynamics among more than 200 French, German, Italian, Spanish, and U.K. rheumatologists through comprehensive primary research methods and how these treatment dynamics have evolved in recent years. This report covers in detail the use of biological products prescribed for RA, and explores rheumatologists’ awareness, trial, and usage of currently available brands, as well as their familiarity with and interest in key emerging therapies.
Questions Answered in This Report:
- The use of biological agents to treat RA has been relatively consistent since 2012. Is there remaining opportunity for novel biological agents in the crowded RA landscape?
- Brand share has shifted away from the established tumor necrosis factor-alpha (TNF-?) inhibitors toward the more recently launched products. How do European rheumatologists anticipate market shares will evolve in the future?
- Because of many existing treatments, promotional messages to differentiate rival brands and education in the use of new brands have become more important in physicians’ prescribing decisions. How are salesforce teams from the leading RA brands interacting with rheumatologists, and what messages are they delivering for key brands? Which sales representatives excel at conveying product information about their respective brand?
- RA has an active pipeline of many novel treatments with alternative mechanisms of action as well as the recently launched first biosimilar agent for use in immunological indications including RA. How will the availability of biosimilar agents and new RA treatments affect rheumatologists’ prescribing habits?
Markets covered: France, Germany, Italy, Spain, United Kingdom.
Primary research: Online survey of 253 European rheumatologists currently in clinical practice, treating a minimum of 25 RA patients, and at least 5 RA patients with a biological agent.
Emerging therapies: Phase III: 5 drugs.